Cencora, Inc. (COR) EV/FCF Ratio: 41.83x
Is Cencora, Inc.’s EV/FCF ratio high or low?
Cencora, Inc.'s EV/FCF ratio of 41.83x is 113% above its 5-year average of 19.61x, around the middle of its 5-year range (11.29x–68.88x).
As of Saturday, June 13, 2026. 21.25% above its 12-month average of 34.50x.
COR EV/FCF Ratio Chart
COR Average EV/FCF Ratio Chart
COR Current vs Average EV/FCF Ratio Chart
COR EV/FCF Ratio Metrics
EV/FCF RATIO
41.83x
EV/FCF RATIO AVG TTM
34.50x
EV/FCF RATIO AVG 3Y
22.64x
EV/FCF RATIO AVG 5Y
19.61x
EV/FCF RATIO AVG 10Y
16.69x
EV/FCF RATIO AVG 15Y
15.75x
EV/FCF RATIO AVG 20Y
14.87x
CURRENT VS TTM AVG
+21.25%
CURRENT VS 3Y AVG
+84.77%
CURRENT VS 5Y AVG
+113.34%
CURRENT VS 10Y AVG
+150.59%
CURRENT VS 15Y AVG
+165.62%
CURRENT VS 20Y AVG
+181.37%
COR Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cencora, Inc. (COR) | $54.80B | 41.83x | 34.50x | 22.64x | 19.61x |
| Becton, Dickinson and Company (BDX) | $52.98B | 18.30x | 23.34x | 27.93x | 30.73x |
| Regeneron Pharmaceuticals, Inc. (REGN) | $63.06B | 15.80x | 18.46x | 23.59x | 21.59x |
| Humana Inc. (HUM) | $45.53B | 43.08x | 33.75x | 21.63x | 31.66x |
| IDEXX Laboratories, Inc. (IDXX) | $44.24B | 42.72x | 56.28x | 56.87x | 65.95x |
| Agilent Technologies, Inc. (A) | $36.67B | 30.59x | 34.61x | 30.04x | 33.45x |
| Zoetis Inc. (ZTS) | $33.36B | 19.15x | 28.04x | 41.96x | 48.22x |
| Centene Corporation (CNC) | $32.19B | 4.32x | 9.55x | 24.73x | 19.03x |
| Medline Inc. (MDLN) | $30.96B | 26.58x | 27.72x | 27.72x | 27.72x |
| Cigna Corporation (CI) | $78.83B | 13.39x | 17.14x | 14.87x | 15.23x |
Cash Flow Valuation Comparison
EV/FCF
41.8x
P/FCF
35.3x
FCF Yield
2.83%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Cencora, Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Cencora, Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Cencora, Inc. (COR)?
- The EV/FCF ratio for COR stock is 41.83x.
- Is Cencora, Inc.'s EV/FCF ratio high or low?
- Cencora, Inc.'s EV/FCF ratio of 41.83x is 113% above its 5-year average of 19.61x, around the middle of its 5-year range (11.29x–68.88x).
- What is the TTM average EV/FCF ratio for Cencora, Inc. (COR)?
- The TTM average EV/FCF ratio for COR stock is 34.50x.
- What is the 3Y average EV/FCF ratio for Cencora, Inc. (COR)?
- The 3Y average EV/FCF ratio for COR stock is 22.64x.
- What is the 5Y average EV/FCF ratio for Cencora, Inc. (COR)?
- The 5Y average EV/FCF ratio for COR stock is 19.61x.
- What is the 10Y average EV/FCF ratio for Cencora, Inc. (COR)?
- The 10Y average EV/FCF ratio for COR stock is 16.69x.
- What is the 15Y average EV/FCF ratio for Cencora, Inc. (COR)?
- The 15Y average EV/FCF ratio for COR stock is 15.75x.
- What is the 20Y average EV/FCF ratio for Cencora, Inc. (COR)?
- The 20Y average EV/FCF ratio for COR stock is 14.87x.
Cencora, Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-12 | 41.83x |
| 2026-06-11 | 41.81x |
| 2026-06-10 | 41.78x |
| 2026-06-09 | 41.57x |
| 2026-06-08 | 40.88x |
| 2026-06-05 | 41.00x |
| 2026-06-04 | 40.41x |
| 2026-06-03 | 39.57x |
| 2026-06-02 | 39.72x |
| 2026-06-01 | 39.71x |
| 2026-05-29 | 40.29x |
| 2026-05-28 | 40.08x |
| 2026-05-27 | 40.00x |
| 2026-05-26 | 40.47x |
| 2026-05-22 | 40.99x |
| 2026-05-21 | 39.80x |
| 2026-05-20 | 39.71x |
| 2026-05-19 | 39.89x |
| 2026-05-18 | 39.35x |
| 2026-05-15 | 38.83x |
| 2026-05-14 | 39.26x |
| 2026-05-13 | 38.58x |
| 2026-05-12 | 39.23x |
| 2026-05-11 | 39.08x |
| 2026-05-08 | 39.25x |
| 2026-05-07 | 38.57x |
| 2026-05-06 | 38.21x |
| 2026-05-05 | 18.26x |
| 2026-05-04 | 18.14x |
| 2026-05-01 | 18.16x |
| 2026-04-30 | 18.37x |
| 2026-04-29 | 18.56x |
| 2026-04-28 | 18.59x |
| 2026-04-27 | 18.49x |
| 2026-04-24 | 18.38x |
| 2026-04-23 | 18.56x |
| 2026-04-22 | 18.39x |
| 2026-04-21 | 18.61x |
| 2026-04-20 | 19.18x |
| 2026-04-17 | 19.43x |
| 2026-04-16 | 19.15x |
| 2026-04-15 | 18.89x |
| 2026-04-14 | 19.02x |
| 2026-04-13 | 18.97x |
| 2026-04-10 | 19.07x |
| 2026-04-09 | 19.15x |
| 2026-04-08 | 19.29x |
| 2026-04-07 | 19.07x |
| 2026-04-06 | 19.07x |
| 2026-04-02 | 19.28x |
| 2026-04-01 | 18.89x |
| 2026-03-31 | 18.70x |
| 2026-03-30 | 18.48x |
| 2026-03-27 | 18.61x |
| 2026-03-26 | 18.91x |
| 2026-03-25 | 19.30x |
| 2026-03-24 | 19.41x |
| 2026-03-23 | 19.05x |
| 2026-03-20 | 19.40x |
| 2026-03-19 | 19.66x |
| 2026-03-18 | 19.30x |
| 2026-03-17 | 19.82x |
| 2026-03-16 | 20.42x |
| 2026-03-13 | 20.64x |
| 2026-03-12 | 20.79x |
| 2026-03-11 | 20.66x |
| 2026-03-10 | 20.76x |
| 2026-03-09 | 21.28x |
| 2026-03-06 | 21.10x |
| 2026-03-05 | 21.15x |
| 2026-03-04 | 21.63x |
| 2026-03-03 | 21.81x |
| 2026-03-02 | 21.87x |
| 2026-02-27 | 21.84x |
| 2026-02-26 | 21.55x |
| 2026-02-25 | 21.35x |
| 2026-02-24 | 21.42x |
| 2026-02-23 | 21.51x |
| 2026-02-20 | 21.25x |
| 2026-02-19 | 21.14x |
| 2026-02-18 | 21.20x |
| 2026-02-17 | 21.19x |
| 2026-02-13 | 21.23x |
| 2026-02-12 | 20.70x |
| 2026-02-11 | 21.50x |
| 2026-02-10 | 21.19x |
| 2026-02-09 | 21.36x |
| 2026-02-06 | 21.15x |
| 2026-02-05 | 20.76x |
| 2026-02-04 | 19.56x |
| 2026-02-03 | 23.85x |
| 2026-02-02 | 23.96x |
| 2026-01-30 | 23.70x |
| 2026-01-29 | 23.27x |
| 2026-01-28 | 23.17x |
| 2026-01-27 | 23.51x |
| 2026-01-26 | 23.47x |
| 2026-01-23 | 23.35x |
| 2026-01-22 | 23.29x |
| 2026-01-21 | 23.25x |
| 2026-01-20 | 23.18x |
| 2026-01-16 | 23.43x |
| 2026-01-15 | 23.46x |
| 2026-01-14 | 23.14x |
| 2026-01-13 | 22.89x |
| 2026-01-12 | 22.67x |
| 2026-01-09 | 22.28x |
| 2026-01-08 | 22.28x |
| 2026-01-07 | 22.56x |
| 2026-01-06 | 22.91x |
| 2026-01-05 | 22.59x |
| 2026-01-02 | 22.47x |
| 2025-12-31 | 22.40x |
| 2025-12-30 | 22.55x |
| 2025-12-29 | 22.55x |
| 2025-12-26 | 22.60x |
| 2025-12-24 | 22.54x |
| 2025-12-23 | 22.57x |
| 2025-12-22 | 22.54x |
| 2025-12-19 | 22.59x |
| 2025-12-18 | 22.57x |
| 2025-12-17 | 22.72x |
| 2025-12-16 | 22.64x |
| 2025-12-15 | 23.16x |
| 2025-12-12 | 22.90x |
| 2025-12-11 | 22.81x |
| 2025-12-10 | 22.58x |
| 2025-12-09 | 22.37x |
| 2025-12-08 | 22.41x |
| 2025-12-05 | 22.52x |
| 2025-12-04 | 22.39x |
| 2025-12-03 | 22.25x |
| 2025-12-02 | 23.18x |
| 2025-12-01 | 23.75x |
| 2025-11-28 | 24.29x |
| 2025-11-26 | 24.26x |
| 2025-11-25 | 24.64x |
| 2025-11-24 | 68.88x |
| 2025-11-21 | 67.76x |
| 2025-11-20 | 67.15x |
| 2025-11-19 | 66.92x |
| 2025-11-18 | 67.07x |
| 2025-11-17 | 67.65x |
| 2025-11-14 | 67.12x |
| 2025-11-13 | 67.72x |
| 2025-11-12 | 67.38x |
| 2025-11-11 | 67.66x |
| 2025-11-10 | 67.59x |
| 2025-11-07 | 66.91x |
| 2025-11-06 | 66.83x |
| 2025-11-05 | 65.76x |
| 2025-11-04 | 64.15x |
| 2025-11-03 | 63.53x |
| 2025-10-31 | 63.00x |
| 2025-10-30 | 63.58x |
| 2025-10-29 | 62.20x |
| 2025-10-28 | 62.63x |
| 2025-10-27 | 62.70x |
| 2025-10-24 | 62.12x |
| 2025-10-23 | 61.41x |
| 2025-10-22 | 61.80x |
| 2025-10-21 | 61.46x |
| 2025-10-20 | 61.21x |
| 2025-10-17 | 60.75x |
| 2025-10-16 | 59.85x |
| 2025-10-15 | 59.88x |
| 2025-10-14 | 59.60x |
| 2025-10-13 | 59.44x |
| 2025-10-10 | 59.61x |
| 2025-10-09 | 58.94x |
| 2025-10-08 | 58.34x |
| 2025-10-07 | 58.02x |
| 2025-10-06 | 57.44x |
| 2025-10-03 | 57.00x |
| 2025-10-02 | 58.00x |
| 2025-10-01 | 58.54x |
| 2025-09-30 | 58.67x |
| 2025-09-29 | 57.91x |
| 2025-09-26 | 57.73x |
| 2025-09-25 | 56.33x |
| 2025-09-24 | 57.96x |
| 2025-09-23 | 56.94x |
| 2025-09-22 | 54.61x |
| 2025-09-19 | 54.82x |
| 2025-09-18 | 54.96x |
| 2025-09-17 | 54.66x |
| 2025-09-16 | 54.82x |
| 2025-09-15 | 55.06x |
| 2025-09-12 | 56.96x |
| 2025-09-11 | 57.01x |
| 2025-09-10 | 55.90x |
| 2025-09-09 | 56.30x |
| 2025-09-08 | 56.16x |
| 2025-09-05 | 55.25x |
| 2025-09-04 | 55.28x |
| 2025-09-03 | 55.70x |
| 2025-09-02 | 55.65x |
| 2025-08-29 | 55.10x |
| 2025-08-28 | 54.80x |
| 2025-08-27 | 54.92x |
| 2025-08-26 | 54.77x |
| 2025-08-25 | 54.53x |
| 2025-08-22 | 55.26x |
| 2025-08-21 | 57.08x |
| 2025-08-20 | 57.16x |
| 2025-08-19 | 55.63x |
| 2025-08-18 | 54.88x |
| 2025-08-15 | 55.30x |
| 2025-08-14 | 55.65x |
| 2025-08-13 | 55.00x |
| 2025-08-12 | 54.67x |
| 2025-08-11 | 54.94x |
| 2025-08-08 | 53.99x |
| 2025-08-07 | 52.84x |
| 2025-08-06 | 53.76x |
| 2025-08-05 | 17.56x |
| 2025-08-04 | 17.63x |
| 2025-08-01 | 17.34x |
| 2025-07-31 | 17.22x |
| 2025-07-30 | 17.53x |
| 2025-07-29 | 17.42x |
| 2025-07-28 | 17.22x |
| 2025-07-25 | 17.45x |
| 2025-07-24 | 17.46x |
| 2025-07-23 | 17.62x |
| 2025-07-22 | 17.59x |
| 2025-07-21 | 17.58x |
| 2025-07-18 | 17.59x |
| 2025-07-17 | 17.67x |
| 2025-07-16 | 17.86x |
| 2025-07-15 | 17.69x |
| 2025-07-14 | 17.82x |
| 2025-07-11 | 17.72x |
| 2025-07-10 | 17.83x |
| 2025-07-09 | 17.99x |
| 2025-07-08 | 17.87x |
| 2025-07-07 | 18.11x |
| 2025-07-03 | 17.77x |
| 2025-07-02 | 17.50x |
| 2025-07-01 | 17.72x |
| 2025-06-30 | 17.97x |
| 2025-06-27 | 17.95x |
| 2025-06-26 | 17.79x |
| 2025-06-25 | 17.56x |
| 2025-06-24 | 17.66x |
| 2025-06-23 | 17.60x |
| 2025-06-20 | 17.63x |
| 2025-06-18 | 17.80x |
| 2025-06-17 | 17.61x |
| 2025-06-16 | 17.57x |
| 2025-06-13 | 17.73x |
| 2025-06-12 | 17.71x |
| 2025-06-11 | 17.25x |
| 2025-06-10 | 17.12x |
| 2025-06-09 | 17.10x |
| 2025-06-06 | 17.37x |
| 2025-06-05 | 17.34x |
| 2025-06-04 | 17.38x |
| 2025-06-03 | 17.52x |
| 2025-06-02 | 17.54x |
Showing the most recent 260 of 4,850 data points. The chart above shows the full history.
Related Metrics
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch